To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
The Yomiuri Shimbun A doctor administers a Daiichi Sankyo Co. vaccine to a patient at a hospital in Itabashi Ward, Tokyo, on Wednesday.
The Yomiuri Shimbun
12:40 JST, December 14, 2023
TOKYO — Shots of the first Japan-made vaccine for the novel coronavirus are finally being administered, nearly four years after the start of the pandemic.
The vaccine, developed by Daiichi Sankyo Co. and targeting the omicron XBB 1.5 variant, uses messenger RNA like the shots made by Pfizer Inc. and Moderna Inc. in the United States, which are also widely used in Japan.
Production and sale of the vaccine for the virus’ original strain was approved by the Health, Labor and Welfare Ministry in August. In September, the XBB variant shot was also approved, and the health ministry contracted with Daiichi Sankyo to purchase 1.4 million doses. The doses will be used for booster shots for those age 12 and older.
